BOT - Anything but charting, page-6990

From Euroz Nov report on BOT..which is on BOT site..

Euroz analyst talk of Net sales , meaning Gross profit based on 287 000 prescriptions ...meaning for every usd 700 Gross sales we get usd 540 net ( paying approx 22% for cost of production and distribution, sharing with derma clinics)..


! Important ! This does not account for 3x US population...we can have a nice UPSIDE!

"United States, underscoring the considerable market opportunity at hand.Based on our analysis, we estimate Kaken sold ~72,000 prescriptions in 2Q, or +287,000prescriptions on an annualised basis (Figure 4).More so, when applied to our estimate of US pricing (US$540/month; net), thisannualised 2Q prescription figure implies ~A$239 million of annual revenues in theUnited States (Figure 5).Additionally, this is based on Japanese prescription volumes, the United States has apopulation nearly 3x larger than Japan – which would suggest even larger potentialprescription volumes and sales are possible. We provide the full analysis below."